KR20230037083A - Composition for preventing, treating or improving influenza virus infection comprising Elaeocarpus sylvestris extract, fraction or phenolic compounds thereof as an active ingredient - Google Patents

Abstract

The present invention relates to a pharmaceutical composition for preventing, treating, or improving influenza virus infection, comprising an extract and fractions of Elaeocarpus sylvestris, or phenolic compounds derived therefrom as an active ingredient. It was confirmed that the extracts and compounds of the present invention can be used for preventing, improving, or treating influenza. According to the present invention, the extracts, fractions of Elaeocarpus sylvestris or phenol compound derived therefrom have no side effects on the human body, have excellent safety, and has excellent antiviral activity. Thus, the present invention is expected to be useful in the prevention or treatment of type A influenza virus infectious disease. The novel use of phenolic compounds derived from Elaeocarpus sylvestris extract, comprising the new compound of the present invention. The novel influenza prevention, improvement or treatment use of phenolic compounds derived from Elaeocarpus sylvestris extract, including the new compound of the present invention are new, previously unknown uses for phenol compounds. In addition, the Elaeocarpus sylvestris extract or the phenol compound derived from the Elaeocarpus sylvestris extract, according to the present invention, shows excellent influenza inhibition ability as a result of molecular docking simulation with influenza virus, and thus, the same can be easily used as a composition for preventing, improving, or treating influenza.

Description

Composition for preventing, treating or improving influenza virus infection comprising Elaeocarpus sylvestris extract, fraction or phenolic compounds thereof as an active ingredient ingredient}

The present invention relates to a composition for preventing, treating, or improving influenza virus infection of an extract, fraction, or phenolic compound derived from Elaeocarpus sylvestris .

Influenza virus, which belongs to Orthomyxoviridae, shows clear systemic symptoms such as fever, muscle pain, and headache compared to the common cold, and the incubation period is about 1 to 3 days, causing 5 million severely ill patients worldwide every year. These influenza viruses are classified into A, B, and C types and have the same overall structure and composition. They have a diameter of 80 to 120 nm and are filament-shaped in the early stage of infection, but become circular in the later stage. Influenza virus, the viral envelope surrounding the central nucleus is largely composed of glycoproteins that can be distinguished into two types, hemagglutinin (H) and neuraminidase (N), and the nucleus is composed of viral RNA (viral RNA). RNA) and viral proteins necessary to protect and activate it. Types B and C have low susceptibility and low genetic diversity, so there are almost no subtypes, and they appear infrequently and do not become prevalent. Depending on the response, it is divided into several subtypes. There are 18 H serotypes and 11 N serotypes in nature, and mainly H1/2/3 and N1/2 cause influenza in humans, and various treatments and vaccines. It was developed and is still being developed.

On the other hand, Dampalsu ( Elaeocarpus sylvestris ) is a deciduous broad-leaved arboreous plant mainly inhabiting Jeju Island in Korea, Japan, and Taiwan. The plant grows up to 20 m tall and has long oval or lanceolate leaves, 6-12 cm long and 1.5-3 cm wide. The root of Dampalsu has been called Sanduyeong in oriental medicine since ancient times, and has been used to treat diseases such as fever, diarrhea, and cough.

On the other hand, it has been known that dampalsu extract has therapeutic and inhibitory effects on coronavirus and varicella-zoster virus, but the preventive, ameliorative or therapeutic effect of influenza virus infection has not been known, and was identified for the first time by the present inventors.

Korean Patent Registration No. 10-1874745

As a result of research for the treatment of influenza A infections, the inventors of the present invention confirmed that the freshwater extract and phenolic compounds derived therefrom had excellent anti-influenza effects, and based on this, the present invention was completed.

Accordingly, an object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of influenza virus infection, comprising an extract or a fraction thereof as an active ingredient.

Another object of the present invention is to provide a pharmaceutical composition for preventing or treating influenza virus infection, comprising at least one selected from the group consisting of a compound represented by Formula 1 below and pharmaceutically acceptable salts thereof. will be.

[Formula 1]

In Formula 1,

When R ₂ is hydrogen,

,

,

,

,

,

또는

이고;R ₁ is hydrogen, a hydroxy group, C ₁ -C ₁₆ alkyl, C ₁ -C ₁₅ alkoxy, C ₃ -C ₁₆ cyclic alkyl, C ₂ -C ₁₅ heterocyclic alkyl,

,

,

,

,

,

or

ego;

When R ₂ is a hydroxyl group,

,

,

또는

이다.R ₁ is a hydroxy group, C ₁ -C ₁₀ alkyl, C ₁ -C ₉ alkoxy, C ₃ -C ₁₀ cyclic alkyl, C ₂ -C ₁₀ heterocyclic alkyl,

,

,

or

am.

Another object of the present invention is to provide a pharmaceutical composition for preventing or treating influenza virus infection, comprising at least one selected from the group consisting of a compound represented by Formula 2 below and pharmaceutically acceptable salts thereof. is to do

[Formula 2]

n is an integer from 0 to 3;

이고;R ₃ is hydrogen, a hydroxy group, C ₁ -C ₁₀ alkyl, C ₁ -C ₉ alkoxy, C ₃ -C ₁₀ cyclic alkyl, C ₂ -C ₉ heterocyclic alkyl, or

ego;

이고;R ₄ is hydrogen, a hydroxy group, C ₁ -C ₁₀ alkyl, C ₁ -C ₉ alkoxy, C ₃ -C ₁₀ cyclic alkyl, C ₂ -C ₉ heterocyclic alkyl, or

ego;

Optionally, adjacent substituents among R ₃ to R ₄ may be linked to form a ring;

R _3a is an oxygen or hydroxyl group;

R _3b and R _4a may be connected to form a ring;

The R _3c and R _4b may be connected to form a ring.

Another object of the present invention is to provide a food composition for preventing or ameliorating influenza virus infection, comprising a fresh water extract as an active ingredient.

Another object of the present invention is to provide a quasi-drug composition for preventing or inhibiting influenza virus infection, comprising a fresh water extract as an active ingredient.

However, the technical problem to be achieved by the present invention is not limited to the above-mentioned problems, and other problems not mentioned can be clearly understood by those skilled in the art from the description below. will be.

In order to achieve the object of the present invention as described above, the present invention provides a pharmaceutical composition for preventing or treating influenza virus infection, comprising an extract or a fraction thereof as an active ingredient.

In addition, the present invention provides a pharmaceutical composition for preventing or treating influenza virus infection, characterized in that it comprises at least one selected from the group consisting of a compound represented by Formula 1 and pharmaceutically acceptable salts thereof.

[Formula 1]

In Formula 1,

When R ₂ is hydrogen,

,

,

,

,

,

또는

이고;R ₁ is hydrogen, a hydroxy group, C ₁ -C ₁₆ alkyl, C ₁ -C ₁₅ alkoxy, C ₃ -C ₁₆ cyclic alkyl, C ₂ -C ₁₅ heterocyclic alkyl,

,

,

,

,

,

or

ego;

When R ₂ is a hydroxyl group,

,

,

또는

이다.R ₁ is a hydroxy group, C ₁ -C ₁₀ alkyl, C ₁ -C ₉ alkoxy, C ₃ -C ₁₀ cyclic alkyl, C ₂ -C ₁₀ heterocyclic alkyl,

,

,

or

am.

In addition, the present invention provides a pharmaceutical composition for preventing or treating influenza virus infection, comprising at least one selected from the group consisting of a compound represented by Formula 2 below and pharmaceutically acceptable salts thereof.

[Formula 2]

n is an integer from 0 to 3;

이고;R ₃ is hydrogen, a hydroxy group, C ₁ -C ₁₀ alkyl, C ₁ -C ₉ alkoxy, C ₃ -C ₁₀ cyclic alkyl, C ₂ -C ₉ heterocyclic alkyl, or

ego;

이고;R ₄ is hydrogen, a hydroxy group, C ₁ -C ₁₀ alkyl, C ₁ -C ₉ alkoxy, C ₃ -C ₁₀ cyclic alkyl, C ₂ -C ₉ heterocyclic alkyl, or

ego;

Optionally, adjacent substituents among R ₃ to R ₄ may be linked to form a ring;

R _3a is an oxygen or hydroxyl group;

R _3b and R _4a may be connected to form a ring;

The R _3c and R _4b may be connected to form a ring.

In addition, the present invention provides a method for preventing or treating influenza virus infection, comprising administering the composition to a subject in need thereof.

In addition, the present invention provides a use for preventing or treating influenza virus infection of a composition comprising an extract or a fraction thereof as an active ingredient.

In addition, the present invention provides a use of a freshwater extract or a fraction thereof for the preparation of a drug for preventing or treating influenza virus infection.

In addition, the present invention provides a food composition for preventing or alleviating influenza virus infection, comprising a fresh water extract as an active ingredient.

In addition, the present invention provides a food composition for preventing or ameliorating influenza virus infection, characterized in that it comprises at least one selected from the group consisting of a compound represented by Formula 1 and a food-acceptable salt thereof.

[Formula 1]

In Formula 1,

When R ₂ is hydrogen,

,

,

,

,

,

또는

이고;R ₁ is hydrogen, a hydroxy group, C ₁ -C ₁₆ alkyl, C ₁ -C ₁₅ alkoxy, C ₃ -C ₁₆ cyclic alkyl, C ₂ -C ₁₅ heterocyclic alkyl,

,

,

,

,

,

or

ego;

When R ₂ is a hydroxyl group,

,

,

또는

이다.R ₁ is a hydroxy group, C ₁ -C ₁₀ alkyl, C ₁ -C ₉ alkoxy, C ₃ -C ₁₀ cyclic alkyl, C ₂ -C ₁₀ heterocyclic alkyl,

,

,

or

am.

In addition, the present invention provides a food composition for preventing or improving influenza virus infection, characterized in that it comprises at least one selected from the group consisting of a compound represented by the following formula (2) and a food-acceptable salt thereof.

[Formula 2]

n is an integer from 0 to 3;

이고;R ₃ is hydrogen, a hydroxy group, C ₁ -C ₁₀ alkyl, C ₁ -C ₉ alkoxy, C ₃ -C ₁₀ cyclic alkyl, C ₂ -C ₉ heterocyclic alkyl, or

ego;

이고;R ₄ is hydrogen, a hydroxy group, C ₁ -C ₁₀ alkyl, C ₁ -C ₉ alkoxy, C ₃ -C ₁₀ cyclic alkyl, C ₂ -C ₉ heterocyclic alkyl, or

ego;

Optionally, adjacent substituents among R ₃ to R ₄ may be linked to form a ring;

R _3a is an oxygen or hydroxyl group;

R _3b and R _4a may be connected to form a ring;

The R _3c and R _4b may be connected to form a ring.

In addition, the present invention provides a quasi-drug composition for preventing or inhibiting influenza virus infection, comprising an extract of dampalsu as an active ingredient.

In addition, the present invention provides a quasi-drug composition for preventing or inhibiting influenza virus infection, characterized in that it comprises at least one selected from the group consisting of a compound represented by Formula 1 and pharmaceutically acceptable salts thereof.

[Formula 1]

In Formula 1,

When R ₂ is hydrogen,

,

,

,

,

,

또는

이고;R ₁ is hydrogen, a hydroxy group, C ₁ -C ₁₆ alkyl, C ₁ -C ₁₅ alkoxy, C ₃ -C ₁₆ cyclic alkyl, C ₂ -C ₁₅ heterocyclic alkyl,

,

,

,

,

,

or

ego;

When R ₂ is a hydroxyl group,

,

,

또는

이다.R ₁ is a hydroxy group, C ₁ -C ₁₀ alkyl, C ₁ -C ₉ alkoxy, C ₃ -C ₁₀ cyclic alkyl, C ₂ -C ₁₀ heterocyclic alkyl,

,

,

or

am.

In addition, the present invention provides a quasi-drug composition for preventing or inhibiting influenza virus infection, characterized in that it contains at least one selected from the group consisting of a compound represented by Formula 2 below and pharmaceutically acceptable salts thereof.

[Formula 2]

n is an integer from 0 to 3;

이고;R ₃ is hydrogen, a hydroxy group, C ₁ -C ₁₀ alkyl, C ₁ -C ₉ alkoxy, C ₃ -C ₁₀ cyclic alkyl, C ₂ -C ₉ heterocyclic alkyl, or

ego;

이고;R ₄ is hydrogen, a hydroxy group, C ₁ -C ₁₀ alkyl, C ₁ -C ₉ alkoxy, C ₃ -C ₁₀ cyclic alkyl, C ₂ -C ₉ heterocyclic alkyl, or

ego;

Optionally, adjacent substituents among R ₃ to R ₄ may be linked to form a ring;

R _3a is an oxygen or hydroxyl group;

R _3b and R _4a may be connected to form a ring;

The R _3c and R _4b may be connected to form a ring.

In one embodiment of the present invention, the freshwater extract may be extracted with one or more solvents selected from the group consisting of water, C ₁ to C ₄ alcohol, ethyl acetate, chloroform, hexane, and mixed solvents thereof.

In another embodiment of the present invention, the fraction is from the group consisting of water, alcohol having 1 to 4 carbon atoms, polar solvent, ethyl acetate, normal butanol ( n -Butanol), non-polar solvent, and mixed solvents thereof It may be extracted with one or more selected solvents.

In another embodiment of the present invention, the freshwater extract may be extracted using 30 to 70% ethanol.

In another embodiment of the present invention, the influenza virus may be an influenza A type H1N1 virus.

In another embodiment of the present invention, the freshwater extract can inhibit the expression of at least one selected from the group consisting of influenza virus M1 and NP genes.

In another embodiment of the present invention, the compound may be at least one selected from the group consisting of compounds represented by Formulas 3 to 16 below.

[Formula 3]

[Formula 4]

[Formula 5]

[Formula 6]

[Formula 7]

[Formula 8]

[Formula 9]

[Formula 10]

[Formula 11]

[Formula 12]

[Formula 13]

[Formula 14]

[Formula 15]

[Formula 16]

In another embodiment of the present invention, the food composition may be a health functional food composition.

In another embodiment of the present invention, the quasi-drug may be at least one selected from the group consisting of disinfectant cleaner, shower foam, gargreen, wet tissue, detergent soap, hand wash, and ointment.

According to the present invention, the extract of fresh water, a fraction thereof, or a phenolic compound derived therefrom has no side effects on the human body, is excellent in safety, and has excellent antiviral activity, so it is expected to be useful in the prevention or treatment of influenza A virus infectious diseases. do. New uses for preventing, ameliorating or treating influenza of phenolic compounds derived from freshwater extracts, including the novel compounds of the present invention, have been found for new uses unknown to existing phenolic compounds. In addition, the freshwater extract or the phenolic compound derived from it according to the present invention shows excellent influenza suppression ability as a result of molecular docking simulation with influenza virus, so it can be easily used as a composition for preventing, improving or treating influenza.

1 shows the solvent phylogenetic fractionation process of the fresh water extract.
Figure 2 shows the process of separating 14 phenolic compounds derived from the fresh water extract.
Figure 3 shows the structural formula of the phenolic compound derived from the fresh water extract.
4a to 4e show the results of an influenza suppression experiment through molecular docking simulation using a phenolic compound derived from a freshwater extract.
Figure 5 shows the results of testing the cytotoxicity of the freshwater extract according to the present invention in MDCK cell lines.
Figure 6 shows the test results of the cell lesion effect and cell viability in the IAV-infected MDCK cell line of the freshwater extract.
7a shows the result of confirming the expression of influenza virus M1 and NP genes according to the treatment of the freshwater extract.
Figure 7b shows the expression level of viral NPs according to the treatment of the freshwater extract through anti-viral NP staining.
7c shows the expression level of the M1 protein according to the treatment of the freshwater extract.
Fig. 8 shows the morphological changes and cytotoxicity of compounds 2 and 3 derived from freshwater extract in MDCK cell line tested.
Fig. 9 shows the test results of cell lesion effects and cell viability of compounds 2 and 3 derived from freshwater extract in an IAV-infected MDCK cell line.
Fig. 10a shows the results of M1 and NP gene expression and IAV viral titer after treatment with compounds 2 and 3 derived from freshwater extract.
Figure 10b shows the expression level of viral NPs according to treatment with compounds 2 and 3 derived from freshwater extract through anti-viral NP staining.
10c shows the expression levels of M1 and NS1 proteins according to the treatment with Compounds 2 and 3 derived from freshwater extract.
11a and 11b show the experimental results of intranasal administration of freshwater extract and compounds 2 and 3 in an animal model infected with influenza virus.
12a and 12b show experimental results of oral administration of freshwater extract in an animal model infected with influenza virus.

In one embodiment of the present invention, solvent-based fractionation was performed on the freshwater extract to obtain a residue of 261 g, and 14 phenolic compounds were isolated from the freshwater extract (see Examples 2 and 3).

In another example of the present invention, the influenza virus inhibitory effect was confirmed through the average binding energy value through the molecular docking simulation of the phenolic compound derived from the fresh water extract (see Example 4).

In another example of the present invention, when MDCK cells were treated with the freshwater extract, it was confirmed that there was no cytotoxicity (see Example 6).

In another example of the present invention, when MDCK cells infected with IAV were treated with the freshwater extract, it was confirmed that CPE was decreased in a concentration-dependent manner and cell viability was increased (see Example 7).

In another embodiment of the present invention, when MDCK cells infected with IAV were treated with the freshwater extract, it was confirmed that the expression of the MI gene, NP gene, and viral M1 protein was suppressed, and the expression level of the viral NP was suppressed, so that the freshwater extract was very effective. It was confirmed that it exhibited an excellent antiviral effect (see Examples 8 and 9).

In another example of the present invention, when MDCK cells were treated with compounds 2 and 3, it was confirmed that there was no morphological change or cytotoxicity of the cells (see Example 10).

In another example of the present invention, when MDCK cells infected with IAV were treated with compounds 2 and 3, it was confirmed that CPE was decreased in a concentration-dependent manner, and cell viability was also increased (see Example 11).

In another embodiment of the present invention, when MDCK cells infected with IAV were treated with compounds 2 and 3, M1 and NP mRNA expression, M1 and NS1 protein expression were suppressed, and both IAV viral titer and viral NP decreased. confirmed (see Examples 12 and 13).

In another embodiment of the present invention, as a result of intranasally administering the freshwater extract and compounds 2 and 3 to IAV-infected mice, the survival rate increased to 80% in the freshwater extract and 100% in compounds 2 and 3, compared to the control group. It was confirmed that it did, and it was confirmed that the width of weight loss decreased (see Example 14).

In another embodiment of the present invention, as a result of orally administering the freshwater extract to IAV-infected mice, it was confirmed that weight loss was suppressed in the oral administration of the freshwater extract compared to the control group, and the expression of M1, which forms the influenza virus structure, was suppressed. It was confirmed that it is (see Example 14).

Hereinafter, the present invention will be described in detail.

Terms used in this specification (terminology) are terms used to appropriately express preferred embodiments of the present invention, which may vary according to the intention of a user or operator or customs in the field to which the present invention belongs. Therefore, definitions of these terms will have to be made based on the content throughout this specification. Throughout the specification, when a certain component is said to "include", it means that it may further include other components without excluding other components unless otherwise stated.

All technical terms used in the present invention, unless defined otherwise, are used with the same meaning as commonly understood by one of ordinary skill in the art related to the present invention. In addition, although preferred methods or samples are described in this specification, those similar or equivalent thereto are also included in the scope of the present invention. The contents of all publications incorporated herein by reference are incorporated herein by reference.

The present invention provides a pharmaceutical composition for the prevention or treatment of influenza virus infection, comprising an extract or a fraction thereof as an active ingredient.

In the present invention, the freshwater extract may be freshwater leaves, stems, branches, roots, or whole plant extracts including all of them . It doesn't work. The freshwater can be directly collected, cultivated, or commercially available without limitation.

Also, in the present invention, the freshwater extract may be mixed with ESE ( E. sylvestris ethanolic extract).

In the present invention, “extract” refers to an extract obtained by the extraction treatment of fresh water, a diluted or concentrated liquid of the extract, a dried product obtained by drying the extract, a crude or purified product of the extract, or a mixture thereof. It includes extracts of all formulations that can be formed using the extract itself and the extract solution. In addition, “extract” may include a crude extract, a polar solvent-soluble extract, or a non-polar solvent-soluble extract. According to one embodiment of the present invention, the freshwater extract may be in the form of a dried product, but is not limited thereto.

In the present invention, the method for extracting freshwater is not particularly limited, and can be extracted according to a method commonly used in the art. For example, a method using an extraction device such as supercritical extraction, subcritical extraction, high-temperature extraction, high-pressure extraction, or ultrasonic extraction, or a method using an adsorption resin including XAD and HP-20 may be used. Non-limiting examples of the extraction method include a heating extraction method, a cold extraction method, a reflux cooling extraction method, a steam distillation method, an ultrasonic extraction method, an elution method, a compression method, and the like, which are performed alone or in combination of two or more methods. It can be. In addition, depending on the purpose, the extract may be additionally subjected to a conventional fractionation process and may be purified according to a conventional purification method.

For example, the extract included in the composition of the present invention may be prepared by pulverizing the primary extract extracted by the hot water extraction or solvent extraction method through an additional process such as distillation under reduced pressure and freeze drying or spray drying. In addition, a purified fraction can be additionally obtained from the primary extract through various chromatography such as silica gel column chromatography, high performance liquid chromatography, and thin layer chromatography. . Therefore, in the present invention, the extract may include all extracts, separated compounds, fractions and purified products obtained in each step of extraction, fractionation or purification, dilution, concentration, or drying thereof.

In the present invention, the type of extraction solvent used for extracting the fresh water is not particularly limited, and according to a conventional method known in the art for extracting an extract from a natural product, that is, under normal temperature and pressure conditions. It can be extracted using a phosphorus solvent. For example, in the present invention, the freshwater extract may be extracted with one or more solvents selected from the group consisting of water, C ₁ to C ₄ alcohol, ethyl acetate, chloroform and hexane, and mixed solvents thereof, and one embodiment of the present invention According to an example, extraction may be performed using ethanol as a solvent, but is not limited thereto. In addition, methanol or ethanol aqueous solution may be used, and the methanol or ethanol aqueous solution is 30 to 90% ( v / v ) or 30 to 70% ( v / v ), more specifically 40 to 60% ( v / v ), Most specifically, it may be 50% ( v/v ) methanol or ethanol, but is not limited thereto.

In the present invention, when fresh water is extracted using ethanol as a solvent, for example, 10% to 100% ethanol, 10% to 90% ethanol, 10% to 80% ethanol, 10% to 70% ethanol, 10% to 70% ethanol 60% ethanol, 10% to 50% ethanol, 20% to 90% ethanol, 20% to 80% ethanol, 20% to 70% ethanol, 20% to 60% ethanol, 20% to 50% ethanol, 30% to 90% % Ethanol, 30% to 80% Ethanol, 30% to 70% Ethanol, 30% to 60% Ethanol, 30% to 50% Ethanol, 40% to 90% Ethanol, 40% to 80% Ethanol, 40% to 70% Ethanol, 40% to 60% ethanol, 40% to 50% ethanol, 45% to 55% ethanol, or 50% ethanol may be used, but is not limited thereto.

The prepared extract may then be filtered or concentrated or dried to remove the solvent, and both filtration, concentration and drying may be performed. For example, filtration may use filter paper or a vacuum filter, concentration may use a vacuum vacuum concentrator or vacuum rotary evaporator, and drying may be performed by vacuum drying, vacuum drying, boiling drying, spray drying, freeze drying, and the like. However, it is not limited thereto.

The number of extractions may be carried out one or more times, but as the extraction continues, the yield of the active ingredient significantly decreases, so it may not be economical to perform the extraction repeatedly five times or more. Accordingly, the number of extractions is preferably 1 to 5 times, and more preferably 2 to 5 repeated extractions, but is not limited thereto.

The freshwater extract may inhibit the expression of one or more selected from the group consisting of influenza virus M1 and NP genes, but is not limited thereto.

In the present invention, "fraction" means a result obtained by performing fractionation to separate a specific component or a specific component group from a mixture containing various components.

The fraction may be extracted with one or more solvents selected from the group consisting of water, alcohol having 1 to 4 carbon atoms, chloroform, ethyl acetate, normal butanol ( n -Butanol), and mixed solvents thereof, but is limited thereto It doesn't work. In addition, it may be extracted with other polar or non-polar solvents.

A fractionation method for obtaining the fraction is not particularly limited, and may be performed according to a method commonly used in the art. Non-limiting examples of the fractionation method include a solvent fractionation method performed by treating various solvents, an ultrafiltration fractionation method performed by passing an ultrafiltration membrane having a constant molecular weight cut-off value, and various chromatography (size, charge, hydrophobicity). or prepared for separation according to affinity), and a combination thereof, according to an embodiment of the present invention, thin-layer chromatography, silica gel column chromatography Silica gel column chromatography Sephadex LH-20 column chromatography and ODS column chromatography may be used, but are not limited thereto.

In addition, as the type of fractionation solvent used to obtain the fraction, any solvent known in the art may be used. Non-limiting examples of the fractionation solvent include polar solvents such as water and alcohol having 1 to 4 carbon atoms; Non-polar solvents such as ethyl acetate and normal butanol ( n -Butanol); or mixed solvents thereof. These may be used alone or in combination of one or more, but are not limited thereto. Specifically, water, methanol, butanol, hexane, ethyl acetate or a mixed solvent thereof may be used.

In addition, the present invention provides a pharmaceutical composition for preventing or treating influenza virus infection, characterized in that it comprises at least one selected from the group consisting of a compound represented by Formula 1 and pharmaceutically acceptable salts thereof.

[Formula 1]

In Formula 1,

When R ₂ is hydrogen,

,

,

,

,

,

또는

이고;R ₁ is hydrogen, a hydroxy group, C ₁ -C ₁₆ alkyl, C ₁ -C ₁₅ alkoxy, C ₃ -C ₁₆ cyclic alkyl, C ₂ -C ₁₅ heterocyclic alkyl,

,

,

,

,

,

or

ego;

When R ₂ is a hydroxyl group,

,

,

또는

이다.R ₁ is a hydroxy group, C ₁ -C ₁₀ alkyl, C ₁ -C ₉ alkoxy, C ₃ -C ₁₀ cyclic alkyl, C ₂ -C ₁₀ heterocyclic alkyl,

,

,

or

am.

In addition, the present invention provides a pharmaceutical composition for preventing or treating influenza virus infection, comprising at least one selected from the group consisting of a compound represented by Formula 2 below and pharmaceutically acceptable salts thereof.

[Formula 2]

n is an integer from 0 to 3;

이고;R ₃ is hydrogen, a hydroxy group, C ₁ -C ₁₀ alkyl, C ₁ -C ₉ alkoxy, C ₃ -C ₁₀ cyclic alkyl, C ₂ -C ₉ heterocyclic alkyl, or

ego;

이고;R ₄ is hydrogen, a hydroxy group, C ₁ -C ₁₀ alkyl, C ₁ -C ₉ alkoxy, C ₃ -C ₁₀ cyclic alkyl, C ₂ -C ₉ heterocyclic alkyl, or

ego;

Optionally, adjacent substituents among R ₃ to R ₄ may be linked to form a ring;

R _3a is an oxygen or hydroxyl group;

R _3b and R _4a may be connected to form a ring;

The R _3c and R _4b may be connected to form a ring.

In the present invention, the compound may be one or more selected from the group consisting of compounds represented by the following formulas 3 to 16, but is not limited thereto.

[Formula 3]

[Formula 4]

[Formula 5]

[Formula 6]

[Formula 7]

[Formula 8]

[Formula 9]

[Formula 10]

[Formula 11]

[Formula 12]

[Formula 13]

[Formula 14]

[Formula 15]

[Formula 16]

In addition, in the present invention, the method for obtaining the compound may be chemically synthesized by a method known in the field to which the present invention belongs, or a commercially available material may be used, and may be obtained by extraction and separation according to an embodiment of the present invention, Not limited to this. The extract or fraction may contain at least one selected from the group consisting of compounds represented by Formulas 3 to 16 as an active ingredient or standard substance, but is not limited thereto. In addition, the extract or fraction may contain a high dose of the compound. However, it is not limited thereto.

The compound may be mixed with water, a polar solvent such as alcohol having 1 to 4 carbon atoms; Non-polar solvents such as ethyl acetate and normal butanol ( n -Butanol); Or it may be a compound obtained by fractionation with a mixed solvent thereof. According to an embodiment of the present invention, an extract of freshwater freshwater was obtained by using 50% ethanol from dried freshwater freshwater leaves, and the extract was mixed with water, methanol, butanol, and hexane. , ethyl acetate, chloroform or a mixed solvent thereof to separate at least one selected from the group consisting of compounds represented by Formulas 3 to 16, but is not limited thereto.

The compound represented by Formula 1 may include at least one selected from the group consisting of compounds represented by Formula 3 and Formulas 6 to 16, but is not limited thereto.

In addition, the compound represented by Formula 2 may include one or more selected from the group consisting of compounds represented by Formulas 4 to 5, but is not limited thereto.

The compound represented by Chemical Formula 3 is kaempferol - 3- O - β -D- ( 2''-galloyl) -xylopyranoside, which is a flavonoid compound derived from fresh water extract. (2''-galloyl)-xylopyranoside), which is a novel compound not previously known, and its structure as well as its presence in freshwater was first identified by the present inventors. Also, it was named elaeocarposide A by the present inventors.

The compound represented by Formula 4 may be a tannin compound derived from a freshwater extract, [(1R,7R,8S,26R,28S,29R,38R)-1,13,14,15,18,19,20,34, 35,39,39-undecahydroxy-2,5,10,23,31-pentaoxo-6,9,24,27,30,40-hexaoxaoctacyclo[34.3.1.0 ^4,38 .0 ^7,26 .0 ^8,29 .0 ^11,16 .0 ^17,22 .0 ^32,37 ]tetraconta-3,11,13,15,17,19,21,32,34,36-decaen-28-yl] 3,4,5- It can have the IUPAC name of trihydroxybenzoate.

The compound represented by Chemical Formula 5 may be a tannin compound derived from a fresh water extract, [(2R,3R,4S,5R,6S)-3,4,5,6-tetrakis[(3,4,5-trihydroxybenzoyl)oxy It can have the IUPAC name of ]oxan-2-yl]methyl 3,4,5-trihydroxybenzoate.

The compound represented by Chemical Formula 6 may be a flavonoid compound derived from a fresh water extract and may have an IUPAC name of 3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromen-4-one.

The compound represented by Formula 7 may be a flavonoid compound derived from a fresh water extract, 3-[(2S,3R,4R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-5 It may have the IUPAC name of ,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one.

The compound represented by Chemical Formula 8 may be a flavonoid compound derived from a fresh water extract, 5,7-dihydroxy-2-(4-hydroxyphenyl)-3-[(2S,3R,4S,5S,6R)-3,4, It can have the IUPAC name of 5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one.

The compound represented by Chemical Formula 9 may be a flavonoid compound derived from a fresh water extract, 5,7-dihydroxy-2-(4-hydroxyphenyl)-3-[(2S,3R,4S,5S)-3,4,5- It can have the IUPAC name of trihydroxyoxan-2-yl]oxychromen-4-one.

The compound represented by Chemical Formula 10 may be a flavonoid compound derived from a fresh water extract, or may be kaempferol-3- O - β -D - xylopyranoside .

The compound represented by Chemical Formula 11 may be a flavonoid compound derived from a fresh water extract, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2S,3R,4S,5S)-3,4, It may have the IUPAC name of 5-trihydroxyoxan-2-yl]oxychromen-4-one.

The compound represented by Chemical Formula 12 may be a flavonoid compound derived from a fresh water extract, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2S,3R,4S,5R,6R)-3, It can have the IUPAC name of 4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one.

The compound represented by Chemical Formula 13 may be a flavonoid compound derived from an extract of dampalsu, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2S,3R,4S,5S,6R)-3, It can have the IUPAC name of 4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one.

The compound represented by Chemical Formula 14 may be a flavonoid compound derived from a fresh water extract, and is 5,7-dihydroxy-2-(4-hydroxyphenyl)-3-[(2S,3R,4S,5R,6R)-3,4, It can have the IUPAC name of 5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one.

The compound represented by Chemical Formula 15 may be a flavonoid compound derived from a fresh water extract, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(3R,4S,5R)-3,4,5- It can have the IUPAC name of trihydroxyoxan-2-yl]oxychromen-4-one.

The compound represented by Chemical Formula 16 may be a flavonoid compound derived from a fresh water extract, kaempferol-3- O - α -L- (2''-galloyl) -arabinopyranoside (kaempferol-3- O - α -L-(2''-galloyl)-arabinopyranoside).

In the present invention, “influenza” refers to an infectious disease caused by an orthomyxoviridae influenza virus among viruses that cause cold symptoms. Compared to the common cold, systemic symptoms such as fever, muscle pain, and headache appear distinctly, and the incubation period is about 1 to 3 days. Influenza is classified into A, B, and C types, and their overall structure and composition are the same. They have a diameter of 80 to 120 nm and are filament-shaped in the early stage of infection, but become circular in the later stage. Influenza virus, the viral envelope surrounding the central nucleus is largely composed of glycoproteins that can be distinguished into two types, hemagglutinin (H) and neuraminidase (N), and the nucleus is composed of viral RNA (viral RNA). RNA) and viral proteins necessary to protect and activate it. Types B and C have low susceptibility and low genetic diversity, so there are almost no subtypes, and they appear infrequently and do not become prevalent. It is again divided into several subtypes according to the reaction. In nature, there are 18 H serotypes and 11 N serotypes, and mainly H1/2/3 and N1/2 are the subtypes that cause influenza in humans. According to one embodiment of the present invention, the influenza virus may be an influenza A type H1N1 virus, but is not limited thereto.

In the present invention, "molecular docking simulation" predicts the binding suitability of a small molecule ligand to an appropriate target binding site based on the association between biologically relevant molecules such as proteins, peptides, nucleic acids, carbohydrates, and lipids, thereby improving structure-based drug design. A method that is often used. In the present invention, influenza inhibitory activity was determined based on the ability to bind to influenza virus proteins.

The pharmaceutical composition according to the present invention may further include suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions. The excipient may be, for example, one or more selected from the group consisting of a diluent, a binder, a disintegrant, a lubricant, an adsorbent, a moisturizer, a film-coating material, and a controlled release additive.

The pharmaceutical compositions according to the present invention are powders, granules, sustained-release granules, enteric granules, solutions, eye drops, elsilic agents, emulsions, suspensions, spirits, troches, perfumes, and limonadese, respectively, according to conventional methods. , tablets, sustained-release tablets, enteric tablets, sublingual tablets, hard capsules, soft capsules, sustained-release capsules, enteric capsules, pills, tinctures, soft extracts, dry extracts, fluid extracts, injections, capsules, perfusate, It can be formulated and used in the form of external preparations such as warning agents, lotions, pasta agents, sprays, inhalants, patches, sterile injection solutions, or aerosols, and the external agents are creams, gels, patches, sprays, ointments, and warning agents. , lotion, liniment, pasta, or cataplasma may have formulations such as the like.

Carriers, excipients and diluents that may be included in the pharmaceutical composition according to the present invention include lactose, dextrose, sucrose, oligosaccharide, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

When formulated, it is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants.

Corn starch, potato starch, wheat starch, lactose, sucrose, glucose, fructose, di-mannitol, precipitated calcium carbonate, synthetic aluminum silicate, phosphoric acid as additives for tablets, powders, granules, capsules, pills, and troches according to the present invention Calcium monohydrogen, calcium sulfate, sodium chloride, sodium bicarbonate, purified lanolin, microcrystalline cellulose, dextrin, sodium alginate, methylcellulose, sodium carboxymethylcellulose, kaolin, urea, colloidal silica gel, hydroxypropyl starch, hydroxypropylmethyl Excipients such as cellulose (HPMC) 1928, HPMC 2208, HPMC 2906, HPMC 2910, propylene glycol, casein, calcium lactate, Primogel; Gelatin, gum arabic, ethanol, agar powder, cellulose phthalate acetate, carboxymethyl cellulose, calcium carboxymethyl cellulose, glucose, purified water, sodium caseinate, glycerin, stearic acid, sodium carboxymethyl cellulose, sodium methyl cellulose, methyl cellulose, microcrystalline cellulose, dextrin Binders such as hydroxycellulose, hydroxypropyl starch, hydroxymethylcellulose, purified shellac, starch arc, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinyl alcohol, and polyvinylpyrrolidone may be used, Hydroxypropyl Methyl Cellulose, Corn Starch, Agar Powder, Methyl Cellulose, Bentonite, Hydroxypropyl Starch, Sodium Carboxymethyl Cellulose, Sodium Alginate, Calcium Carboxymethyl Cellulose, Calcium Citrate, Sodium Lauryl Sulfate, Silicic Anhydride, 1-Hydroxy Propyl cellulose, dextran, ion exchange resin, polyvinyl acetate, formaldehyde-treated casein and gelatin, alginic acid, amylose, guar gum, sodium bicarbonate, polyvinylpyrrolidone, calcium phosphate, gelled starch, gum arabic, disintegrants such as amylopectin, pectin, sodium polyphosphate, ethyl cellulose, white sugar, magnesium aluminum silicate, di-sorbitol solution, and light anhydrous silicic acid; Calcium stearate, magnesium stearate, stearic acid, hydrogenated vegetable oil, talc, lycopod, kaolin, vaseline, sodium stearate, cacao butter, sodium salicylate, magnesium salicylate, polyethylene glycol 4000, 6000, liquid paraffin, hydrogenated soybean oil (Lubri wax), aluminum stearate, zinc stearate, sodium lauryl sulfate, magnesium oxide, macrogol, synthetic aluminum silicate, silicic anhydride, higher fatty acid, higher alcohol, silicone oil, paraffin oil, polyethylene glycol fatty acid ether, starch, sodium chloride, A lubricant such as sodium acetate, sodium oleate, dl-leucine, light anhydrous silicic acid; may be used.

Additives for the liquid formulation according to the present invention include water, dilute hydrochloric acid, dilute sulfuric acid, sodium citrate, sucrose monostearate, polyoxyethylene sorbitol fatty acid esters (tween esters), polyoxyethylene monoalkyl ethers, lanolin ethers, Lanolin esters, acetic acid, hydrochloric acid, aqueous ammonia, ammonium carbonate, potassium hydroxide, sodium hydroxide, prolamine, polyvinylpyrrolidone, ethyl cellulose, sodium carboxymethyl cellulose, and the like may be used.

In the syrup according to the present invention, a solution of white sugar, other sugars, or a sweetener may be used, and aromatics, coloring agents, preservatives, stabilizers, suspending agents, emulsifiers, thickeners, etc. may be used as necessary.

Purified water may be used in the emulsion according to the present invention, and emulsifiers, preservatives, stabilizers, fragrances, etc. may be used as needed.

Acacia, tragacantha, methylcellulose, carboxymethylcellulose, carboxymethylcellulose sodium, microcrystalline cellulose, sodium alginate, hydroxypropylmethylcellulose, HPMC 1828, HPMC 2906, HPMC 2910, etc. and, if necessary, surfactants, preservatives, stabilizers, colorants, and fragrances may be used.

Injections according to the present invention include distilled water for injection, 0.9% sodium chloride injection, IV injection, dextrose injection, dextrose + sodium chloride injection, PEG, lactated IV injection, ethanol, propylene glycol, non-volatile oil-sesame oil , solvents such as cottonseed oil, peanut oil, soybean oil, corn oil, ethyl oleate, isopropyl myristate, and benzene benzoate; solubilizing agents such as sodium benzoate, sodium salicylate, sodium acetate, urea, urethane, monoethylacetamide, butazolidine, propylene glycol, twins, nijuntinamide, hexamine, and dimethylacetamide; buffers such as weak acids and their salts (acetic acid and sodium acetate), weak bases and their salts (ammonia and ammonium acetate), organic compounds, proteins, albumin, peptone, and gums; tonicity agents such as sodium chloride; Stabilizers such as sodium bisulfite (NaHSO3) carbon dioxide gas, sodium metabisulfite (Na2S2O5), sodium sulfite (Na2SO3), nitrogen gas (N2), ethylenediaminetetraacetic acid; Sulfating agents such as sodium bisulfide 0.1%, sodium formaldehyde sulfoxylate, thiourea, ethylenediamine disodium tetraacetate, acetone sodium bisulfite; analgesics such as benzyl alcohol, chlorobutanol, procaine hydrochloride, glucose, and calcium gluconate; Suspending agents such as Siemesis sodium, sodium alginate, Tween 80, aluminum monostearate may be included.

The suppository according to the present invention includes cacao butter, lanolin, witapsol, polyethylene glycol, glycerogelatin, methylcellulose, carboxymethylcellulose, a mixture of stearic acid and oleic acid, subanal, cottonseed oil, peanut oil, palm oil, cacao butter + Cholesterol, Lecithin, Lannet Wax, Glycerol Monostearate, Tween or Span, Imhausen, Monolen (Propylene Glycol Monostearate), Glycerin, Adeps Solidus, Buytyrum Tego-G -G), Cebes Pharma 16, Hexalide Base 95, Cotomar, Hydroxycote SP, S-70-XXA, S-70-XX75 (S-70-XX95), Hyde Hydrokote 25, Hydrokote 711, Idropostal, Massa estrarium (A, AS, B, C, D, E, I, T), Massa-MF, Masupol, Masupol-15, Neosupostal-N, Paramound-B, Suposiro (OSI, OSIX, A, B, C, D, H, L), suppository type IV (AB, B, A, BC, BBG, E, BGF, C, D, 299), Supostal (N, Es), Wecobi (W, R, S, M, Fs), testosterone triglyceride base (TG-95, MA, 57) and The same mechanism can be used.

Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations contain at least one excipient, for example, starch, calcium carbonate, sucrose, etc. ) or by mixing lactose and gelatin. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used.

Liquid preparations for oral administration include suspensions, solutions for oral administration, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, aromatics, and preservatives may be included. there is. Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried formulations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspending agents.

The pharmaceutical composition according to the present invention is administered in a pharmaceutically effective amount. In the present invention, "pharmaceutically effective amount" means an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level is the type of patient's disease, severity, activity of the drug, It may be determined according to factors including sensitivity to the drug, administration time, route of administration and excretion rate, duration of treatment, drugs used concurrently, and other factors well known in the medical field.

The pharmaceutical composition according to the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered single or multiple times. Considering all of the above factors, it is important to administer an amount that can obtain the maximum effect with the minimum amount without side effects, which can be easily determined by a person skilled in the art to which the present invention belongs.

The pharmaceutical composition of the present invention can be administered to a subject by various routes. All modes of administration can be envisaged, eg oral administration, subcutaneous injection, intraperitoneal administration, intravenous injection, intramuscular injection, paraspinal space (intrathecal) injection, sublingual administration, buccal administration, intrarectal insertion, vaginal It can be administered by intraoral insertion, ocular administration, otic administration, nasal administration, inhalation, spraying through the mouth or nose, dermal administration, transdermal administration, and the like.

The pharmaceutical composition of the present invention is determined according to the type of drug as an active ingredient together with various related factors such as the disease to be treated, the route of administration, the age, sex, weight and severity of the disease of the patient.

In the present invention, "individual" means a subject in need of treatment of a disease, and more specifically, a human or non-human primate, mouse, rat, dog, cat, horse, cow, etc. of mammals.

In the present invention, "administration" means providing a given composition of the present invention to a subject by any suitable method. In the present invention, “prevention” refers to any action that suppresses or delays the onset of a desired disease, and “treatment” means that the desired disease and its resulting metabolic abnormality are improved or improved by administration of the pharmaceutical composition according to the present invention. All actions that are advantageously altered are meant, and "improvement" means any action that reduces a parameter related to a target disease, for example, the severity of a symptom, by administration of the composition according to the present invention.

The present invention provides a food composition for preventing or ameliorating influenza virus infection, comprising an extract of fresh water as an active ingredient.

In addition, it provides a food composition for preventing or improving influenza virus infection, characterized in that it comprises at least one selected from the group consisting of a compound represented by the following formula (1) and a food-acceptable salt thereof.

[Formula 1]

In Formula 1,

When R ₂ is hydrogen,

,

,

,

,

,

또는

이고;R ₁ is hydrogen, a hydroxy group, C ₁ -C ₁₆ alkyl, C ₁ -C ₁₅ alkoxy, C ₃ -C ₁₆ cyclic alkyl, C ₂ -C ₁₅ heterocyclic alkyl,

,

,

,

,

,

or

ego;

When R ₂ is a hydroxyl group,

,

,

또는

이다.R ₁ is a hydroxy group, C ₁ -C ₁₀ alkyl, C ₁ -C ₉ alkoxy, C ₃ -C ₁₀ cyclic alkyl, C ₂ -C ₁₀ heterocyclic alkyl,

,

,

or

am.

In addition, it provides a food composition for preventing or improving influenza virus infection, characterized in that it comprises at least one selected from the group consisting of a compound represented by the following formula (2) and a food-acceptable salt thereof.

[Formula 2]

n is an integer from 0 to 3;

이고;R ₃ is hydrogen, hydroxy group, C ₁ -C ₁₀ alkyl, C ₁ -C ₉ alkoxy, C ₃ -C ₁₀ cyclic alkyl, C ₂ -C ₉ heterocyclic alkyl, or

ego;

이고;R ₄ is hydrogen, a hydroxyl group, C ₁ -C ₁₀ alkyl, C ₁ -C ₉ alkoxy, C ₃ -C ₁₀ cyclic alkyl, C ₂ -C ₉ heterocyclic alkyl, or

ego;

Optionally, adjacent substituents among R ₃ to R ₄ may be linked to form a ring;

R _3a is an oxygen or hydroxyl group;

R _3b and R _4a may be connected to form a ring;

The R _3c and R _4b may be connected to form a ring.

In the present invention, "food" means a natural product or processed product containing one or more nutrients, preferably means a state that can be eaten directly through a certain degree of processing process, and usually means As, it means to include all health functional foods, beverages, food additives and beverage additives.

In the present invention, the food composition may be a health functional food composition, but is not limited thereto.

In the present invention, the "functional food" is the same term as food for special health use (FoSHU), medicine processed to efficiently display bioregulatory functions in addition to nutritional supply, It means a food with high medical effect, and can be manufactured into tablets, capsules, pills, granules, powders, liquids, flakes, pastes, syrups, gels, jellies, bars, or film formulations. Here, "functionality" means obtaining useful effects for health purposes such as regulating nutrients for the structure and function of the human body or physiological functions.

When the extract, fraction, or phenolic compounds derived from these extracts of the present invention are used as food additives, they can be added as is or used together with other foods or food ingredients, and can be appropriately used according to conventional methods. The mixing amount of the active ingredient may be appropriately determined according to the purpose of use (prevention, health or therapeutic treatment). In general, when preparing food or beverage, the freshwater extract of the present invention may be added in an amount of 15% by weight or less, or 10% by weight or less based on the raw material. However, in the case of long-term intake for the purpose of health and hygiene or health control, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount greater than the above range.

There is no particular limitation on the type of food. Examples of foods to which the above substances can be added include meat, sausages, bread, chocolates, candies, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice creams, various soups, beverages, tea, drinks, There are alcoholic beverages and vitamin complexes, and includes all health functional foods in a conventional sense.

The health beverage composition according to the present invention may contain various flavoring agents or natural carbohydrates as additional components, like conventional beverages. The aforementioned natural carbohydrates are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrins and cyclodextrins, and sugar alcohols such as xylitol, sorbitol and erythritol. As the sweetener, natural sweeteners such as thaumatin and stevia extract, or synthetic sweeteners such as saccharin and aspartame may be used. The proportion of the natural carbohydrate is generally about 0.01-0.20 g, or about 0.04-0.10 g per 100 mL of the composition of the present invention.

In addition to the above, the composition of the present invention contains various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, A carbonation agent used in carbonated beverages and the like may be contained. In addition, the composition of the present invention may contain fruit flesh for preparing natural fruit juice, fruit juice beverages and vegetable beverages. These components may be used independently or in combination. The ratio of these additives is not critical, but is generally selected in the range of 0.01-0.20 parts by weight per 100 parts by weight of the composition of the present invention.

In addition, the present invention provides a quasi-drug composition for preventing or inhibiting influenza virus infection, comprising an extract of dampalsu as an active ingredient.

In addition, the present invention provides a quasi-drug composition for preventing or inhibiting influenza virus infection, characterized in that it comprises at least one selected from the group consisting of a compound represented by Formula 1 and pharmaceutically acceptable salts thereof.

[Formula 1]

In Formula 1,

When R ₂ is hydrogen,

,

,

,

,

,

또는

이고;R ₁ is hydrogen, a hydroxy group, C ₁ -C ₁₆ alkyl, C ₁ -C ₁₅ alkoxy, C ₃ -C ₁₆ cyclic alkyl, C ₂ -C ₁₅ heterocyclic alkyl,

,

,

,

,

,

or

ego;

When R ₂ is a hydroxyl group,

,

,

또는

이다.R ₁ is a hydroxy group, C ₁ -C ₁₀ alkyl, C ₁ -C ₉ alkoxy, C ₃ -C ₁₀ cyclic alkyl, C ₂ -C ₁₀ heterocyclic alkyl,

,

,

or

am.

In addition, the present invention provides a quasi-drug composition for preventing or inhibiting influenza virus infection, characterized in that it contains at least one selected from the group consisting of a compound represented by Formula 2 below and pharmaceutically acceptable salts thereof.

[Formula 2]

n is an integer from 0 to 3;

이고;R ₃ is hydrogen, a hydroxy group, C ₁ -C ₁₀ alkyl, C ₁ -C ₉ alkoxy, C ₃ -C ₁₀ cyclic alkyl, C ₂ -C ₉ heterocyclic alkyl, or

ego;

이고;R ₄ is hydrogen, a hydroxy group, C ₁ -C ₁₀ alkyl, C ₁ -C ₉ alkoxy, C ₃ -C ₁₀ cyclic alkyl, C ₂ -C ₉ heterocyclic alkyl, or

ego;

Optionally, adjacent substituents among R ₃ to R ₄ may be linked to form a ring;

R _3a is an oxygen or hydroxyl group;

R _3b and R _4a may be connected to form a ring;

The R _3c and R _4b may be connected to form a ring.

In the "quasi-drug composition for preventing or inhibiting influenza virus infection" according to the present invention, the quasi-drug is a preparation used for sterilization, insecticide, and similar purposes for the prevention of infectious diseases described in Article 2, Item 7, Item C of the Pharmaceutical Affairs Act, and is used for human or animal It may refer to repellents, repellents, preventives, pesticides, or attracting insecticides such as flies and mosquitoes used for the health of people.

In addition, the quasi-drugs may include external skin preparations and personal hygiene products. For example, it may be a disinfectant cleaner, shower foam, gargreen, wet tissue, detergent soap, hand wash, or ointment, but is not limited thereto.

When the quasi-drug composition according to the present invention is used as a quasi-drug additive, the composition may be added as it is or used together with other quasi-drugs or quasi-drug ingredients, and may be appropriately used according to a conventional method. The mixing amount of the active ingredient may be appropriately determined depending on the purpose of use.

The quasi-drug composition of the present invention may be prepared in the form of, for example, a general emulsified formulation and a solubilized formulation. For example, it may have formulations such as emulsions, creams, ointments, sprays, oil gels, gels, oils, aerosols, and smokers such as lotions, but it may be used without limitation as long as it exhibits the pest control inducing effect of the present invention. . In addition, the quasi-drug composition is appropriately mixed as necessary with oil, water, surfactant, moisturizer, lower alcohol having 1 to 4 carbon atoms, thickener, chelating agent, colorant, preservative or flavoring agent, which are generally formulated in quasi-drug compositions, in each dosage form and can be used.

Hereinafter, a preferred embodiment is presented to aid understanding of the present invention. However, the following examples are provided to more easily understand the present invention, and the content of the present invention is not limited by the following examples.

Example 1. Preparation of fresh water extract

Domestic dampalsu leaves from Jeju Island were obtained, dried, cut into pieces, and 100 kg of dampalsu leaves were extracted with 2,000 L of 50% ethanol at 60 ° C for 16 hours. After filtering and concentrating, they were dried under reduced pressure to obtain 28 kg of dampalsu extract (yield 28%). got

Example 2. Fractions derived from fresh water extract through solvent-based fractionation

For the purification of active ingredients, water (500 mL) was continuously poured into 1 kg of the obtained fresh water extract, and n-butanol (n-BuOH, 4 L × 4) and ethyl acetate (EtOAc, 5 L × 4) were added. Distribution extraction was performed using The fractions were assayed by TLC (thin-layer chromatography), and the EtOAc fraction (ESE), a fraction high in phenolic compounds, was concentrated under reduced pressure to obtain 261 g of residue. This process is shown in Figure 1.

Example 3. Purification of phenolic compounds derived from fresh water extract and determination of chemical structure

14×19 cm)을 이용하여 CHCl₃-MeOH (40:1→30:1→10:1→5:1, 각각 16.2 L)로 용출하였고, 19개의 분획물(ESE-1 ~ ESE-19)을 얻었다.For the EtOAc fraction, SiO ₂ cc (SiO ₂ Column chromatography,

14 × 19 cm) was eluted with CHCl ₃ -MeOH (40:1→30:1→10:1→5:1, 16.2 L each), and 19 fractions (ESE-1 to ESE-19) were obtained. got it

5×10 cm)을 이용하여 acetone-물 (2:1, 6.6 L)로 용출하였고, 12개의 분획물(ESE-12-1 ~ ESE-12-12)을 얻었다.Among the 19 fractions, the ESE-12 fraction [7.7 g, eluent/total volume (Ve/Vt) 0.491-0.591] was ODS cc (

5 × 10 cm) and eluted with acetone-water (2:1, 6.6 L), and 12 fractions (ESE-12-1 to ESE-12-12) were obtained.

5.5×10 cm)을 이용하여 acetone-물 (1:1, 2.0 L)로 용출하였고, 8개의 분획물(ESE-12-2-1 ~ ESE-12-2-8)을 얻었다.Among the 12 fractions, the ESE-12-2 fraction [6.7 g, Ve / Vt 0.491-0.591] was ODS cc (

5.5 × 10 cm) and eluted with acetone-water (1:1, 2.0 L), and 8 fractions (ESE-12-2-1 to ESE-12-2-8) were obtained.

1.5×55 cm)을 이용하여 MeOH 1.0 L로 용출하였고, 10개의 분획물(ESE-12-2-5-1 ~ ESE-12-2-5-10)을 얻었다. 이후, 상기 10개의 분획물 중 ESE-12-2-5-8 분획물에서 화합물 4 [34.7 mg, Ve/Vt 0.460-0.550, TLC(Kieselgel 60 F₂₅₄) Rf 0.62, CHCl₃-MeOH(7:1), TLC(RP-18F_254S) Rf 0.46, MeOH-물(3:1)]를 분리하였다.Among the 8 fractions, the ESE-12-2-5 fraction [178.0 mg, Ve/Vt 0.090-0.170] was mixed with Sephadex LH-20 cc (

1.5 × 55 cm) and eluted with 1.0 L of MeOH, and 10 fractions (ESE-12-2-5-1 to ESE-12-2-5-10) were obtained. Then, compound 4 [34.7 mg, Ve/Vt 0.460-0.550, TLC (Kieselgel 60 F ₂₅₄ ) Rf 0.62, CHCl ₃ -MeOH (7: 1) in the ESE-12-2-5-8 fraction among the 10 fractions , TLC (RP-18F _254S ) Rf 0.46, MeOH-water (3:1)] were separated.

5×11 cm)을 이용하여 MeOH-물 (1:1, 1 L)로 용출하였고, 3개의 분획물(ESE-17-1 ~ ESE-17-3)을 얻었다.In addition, among the 19 fractions, the ESE-17 fraction [9.7 g, Ve / Vt 0.799-0.884] was ODS cc (

5×11 cm) and eluted with MeOH-water (1:1, 1 L), and three fractions (ESE-17-1 to ESE-17-3) were obtained.

4×16 cm)을 이용하여 CHCl₃-MeOH-물 (15:3:1→10:3:1, 각각 2.85 L)로 용출하였고, 14개의 분획물(ESE-17-2-1 ~ ESE-17-2-14)을 얻었다.Among the three fractions, the ESE-17-2 fraction [5.9 g, Ve / Vt 0.050-0.560] was SiO ₂ cc (

4 × 16 cm) and eluted with CHCl ₃ -MeOH-water (15:3:1→10:3:1, 2.85 L each), and 14 fractions (ESE-17-2-1 ~ ESE-17 -2-14) was obtained.

1×55 cm)을 이용하여 MeOH 1.0 L로 용출하였고, 5개의 분획물(ESE-17-2-4-1 ~ ESE-17-2-4-5)을 얻었다. 이후, 상기 5개의 분획물 중 ESE-17-2-4-4 분획물에서 화합물 5 [4.3 mg, Ve/Vt 0.320-0.360, TLC(Kieselgel 60 F₂₅₄) Rf 0.45, CHCl₃-MeOH-물(10:3:1), TLC(RP-18F_254S) Rf 0.45, MeOH-물(3:2)]를 분리하였다.Among the 14 fractions, the ESE-17-2-4 fraction [178.0 mg, Ve/Vt 0.133-0.167] was purified by Sephadex LH-20 cc (

1 × 55 cm) was used to elute with 1.0 L of MeOH, and five fractions (ESE-17-2-4-1 to ESE-17-2-4-5) were obtained. Then, compound 5 [4.3 mg, Ve / Vt 0.320-0.360, TLC (Kieselgel 60 F ₂₅₄ ) Rf 0.45, CHCl ₃ -MeOH-water (10: 3:1), TLC (RP-18F _254S ) Rf 0.45, MeOH-water (3:2)] were separated.

1.5×55 cm)을 이용하여 MeOH 1.3 L로 용출하였고, 8개의 분획물(ESE-17-2-8-1 ~ ESE-17-2-8-8)을 얻었다. 이후, 상기 8개의 분획물 중 ESE-17-2-8-4 분획물[41.9 mg, Ve/Vt 0.354-0.385]에 대하여 Preparative HPLC (Waters 600S)을 활용하여 정제를 진행하였다. 이때 컬럼으로 Cosmosil 5C18 column (Waters, 5 μm, 250×10 mm)를 사용하였으며, 254 nm 조건하에 isocratic (0.1% formic acid in DW 70%, acetonitrile 30%)조건으로 용출시켰다. 이때 용출속도는 4.0 μL/min로 하였다. 이를 통하여 화합물 7 [13.9 mg, TLC(Kieselgel 60 F₂₅₄) Rf 0.52, CHCl₃-MeOH-물(8:3:1), TLC(RP-18F_254S) Rf 0.37, MeOH-물(3:2)] 및 화합물 8 [28.0 mg, TLC(Kieselgel 60 F₂₅₄) Rf 0.52, CHCl₃-MeOH-물(8:3:1), TLC(RP-18F_254S) Rf 0.37, MeOH-물(3:2)]을 분리하였다.Subsequently, among the 14 fractions, the ESE-17-2-8 fraction [269.0 mg, Ve / Vt 0.303-0.330] was prepared by Sephadex LH-20 cc (

1.5 × 55 cm) and eluted with 1.3 L of MeOH, and 8 fractions (ESE-17-2-8-1 to ESE-17-2-8-8) were obtained. Thereafter, the ESE-17-2-8-4 fraction [41.9 mg, Ve/Vt 0.354-0.385] among the 8 fractions was purified using Preparative HPLC (Waters 600S). At this time, Cosmosil 5C18 column (Waters, 5 μm, 250 × 10 mm) was used as a column, and elution was performed under isocratic (0.1% formic acid in DW 70%, acetonitrile 30%) conditions under 254 nm conditions. At this time, the dissolution rate was 4.0 μL/min. Through this, compound 7 [13.9 mg, TLC (Kieselgel 60 F ₂₅₄ ) Rf 0.52, CHCl ₃ -MeOH-water (8: 3: 1), TLC (RP-18F _254S ) Rf 0.37, MeOH-water (3: 2) ] and compound 8 [28.0 mg, TLC (Kieselgel 60 F ₂₅₄ ) Rf 0.52, CHCl ₃ -MeOH-water (8:3:1), TLC (RP-18F _254S ) Rf 0.37, MeOH-water (3:2) ] was isolated.

3×6 cm)을 이용하여 MeOH-물 (2:3, 110 mL)로 용출하였고, 7개의 분획물(ESE-17-2-10-1 ~ ESE-17-2-10-7)을 얻었다. 이후, 상기 7개의 분획물 중 ESE-17-2-10-6 분획물[58.1 mg, Ve/Vt 0.265-0.345]에 대하여 Preparative HPLC (Waters 600S)을 활용하여 정제를 진행하였다. 이때 컬럼으로 Cosmosil 5C18 column (Waters, 5 μm, 250×10 mm)를 사용하였으며, 254 nm 조건하에 isocratic (0.1% formic acid in DW 70%, acetonitrile 30%)조건으로 용출시켰다. 이때 용출속도는 4.0 μL/min로 하였다. 이를 통하여 화합물 6 [37.4 mg, TLC(Kieselgel 60 F₂₅₄) Rf 0.51, CHCl₃-MeOH-물(8:3:1), TLC(RP-18F_254S) Rf 0.60, MeOH-물(3:2)] 및 화합물 9 [20.7 mg, TLC(Kieselgel 60 F₂₅₄) Rf 0.52, CHCl₃-MeOH-물(8:3:1), TLC(RP-18F_254S) Rf 0.60, MeOH-물(3:2)]를 분리하였다.Subsequently, among the 14 fractions, the ESE-17-2-10 fraction [876.6 mg, Ve / Vt 0.453-0.633] was ODS cc (

3 × 6 cm) was used to elute with MeOH-water (2:3, 110 mL), and 7 fractions (ESE-17-2-10-1 to ESE-17-2-10-7) were obtained. Thereafter, the ESE-17-2-10-6 fraction [58.1 mg, Ve/Vt 0.265-0.345] among the 7 fractions was purified using Preparative HPLC (Waters 600S). At this time, Cosmosil 5C18 column (Waters, 5 μm, 250 × 10 mm) was used as a column, and elution was performed under isocratic (0.1% formic acid in DW 70%, acetonitrile 30%) conditions under 254 nm conditions. At this time, the dissolution rate was 4.0 μL/min. Through this, compound 6 [37.4 mg, TLC (Kieselgel 60 F ₂₅₄ ) Rf 0.51, CHCl ₃ -MeOH-water (8: 3: 1), TLC (RP-18F _254S ) Rf 0.60, MeOH-water (3: 2) ] and compound 9 [20.7 mg, TLC (Kieselgel 60 F ₂₅₄ ) Rf 0.52, CHCl ₃ -MeOH-water (8:3:1), TLC (RP-18F _254S ) Rf 0.60, MeOH-water (3:2) ] was isolated.

2.5×6 cm)을 이용하여 MeOH-물 (2:3→1:1, 110 mL)로 용출하였고, 15개의 분획물(ESE-17-2-13-1 ~ ESE-17-2-13-15)을 얻었다. 이후, 상기 15개의 분획물 중 ESE-17-2-13-7 분획물에서 화합물 2 [43.7 mg, Ve/Vt 0.100-0.153, TLC(Kieselgel 60 F₂₅₄) Rf 0.49, CHCl₃-MeOH-물(65:35:10), TLC(RP-18F_254S) Rf 0.65, MeOH-물(1:1)]를 분리하였다. 또한 상기 15개의 분획물 중 ESE-17-2-13-11 분획물[28.5 mg, Ve/Vt 0.501-0.633]에 대하여 Preparative HPLC (Waters 600S)을 활용하여 정제를 진행하였다. 이때 컬럼으로 Cosmosil 5C18 column (Waters, 5 μm, 250×10 mm)를 사용하였으며, 254 nm 조건하에 isocratic (0.1% formic acid in DW 70%, acetonitrile 30%)조건으로 용출시켰다. 이때 용출속도는 4.0 μL/min로 하였다. 이를 통하여 화합물 12 [9.7 mg, TLC(Kieselgel 60 F₂₅₄) Rf 0.51, CHCl₃-MeOH-물(65:35:10), TLC(RP-18F_254S) Rf 0.35, MeOH-물(1:1)] 및 화합물 13 [18.8 mg, TLC(Kieselgel 60 F₂₅₄) Rf 0.51, CHCl₃-MeOH-물(65:35:10), TLC(RP-18F_254S) Rf 0.37, MeOH-물(1:1)]을 분리하였다. Subsequently, among the 14 fractions, the ESE-17-2-13 fraction [320.0 mg, Ve / Vt 0.453-0.633] was ODS cc (

2.5 × 6 cm) and eluted with MeOH-water (2:3→1:1, 110 mL), and 15 fractions (ESE-17-2-13-1 ~ ESE-17-2-13-15 ) was obtained. Then, compound 2 [43.7 mg, Ve/Vt 0.100-0.153, TLC (Kieselgel 60 F ₂₅₄ ) Rf 0.49, CHCl ₃ -MeOH-water (65: 35:10), TLC (RP-18F _254S ) Rf 0.65, MeOH-water (1:1)] were separated. Also, among the 15 fractions, the ESE-17-2-13-11 fraction [28.5 mg, Ve/Vt 0.501-0.633] was purified using Preparative HPLC (Waters 600S). At this time, Cosmosil 5C18 column (Waters, 5 μm, 250 × 10 mm) was used as a column, and elution was performed under isocratic (0.1% formic acid in DW 70%, acetonitrile 30%) conditions under 254 nm conditions. At this time, the dissolution rate was 4.0 μL/min. Through this, compound 12 [9.7 mg, TLC (Kieselgel 60 F ₂₅₄ ) Rf 0.51, CHCl ₃ -MeOH-water (65:35:10), TLC (RP-18F _254S ) Rf 0.35, MeOH-water (1:1) ] and compound 13 [18.8 mg, TLC (Kieselgel 60 F ₂₅₄ ) Rf 0.51, CHCl ₃ -MeOH-water (65:35:10), TLC (RP-18F _254S ) Rf 0.37, MeOH-water (1:1) ] was isolated.

7×15 cm)을 이용하여 CHCl₃-MeOH-물 (13:3:1→10:3:1, 각 2.2 L)로 용출하였고, 11개의 분획물(ESE-18-1 ~ ESE-18-11)을 얻었다.In addition, among the 19 fractions, the ESE-18 fraction [31.0 g, Ve / Vt 0.814-0.910] was SiO ₂ cc (

7×15 cm) and eluted with CHCl ₃ -MeOH-water (13:3:1→10:3:1, 2.2 L each), and 11 fractions (ESE-18-1 ~ ESE-18-11 ) was obtained.

4×18 cm)을 이용하여 EtOAc-BuOH-물 (50:3:1→23:3:1→13:3:1, 각 1.5 L)로 용출하였고, 11개의 분획물(ESE-18-8-1 ~ ESE-18-8-11)을 얻었다.Among the 11 fractions, the ESE-18-8 fraction [1.7 g, Ve / Vt 0.617-0.763] was SiO ₂ cc (

4 × 18 cm) and eluted with EtOAc-BuOH-water (50:3:1→23:3:1→13:3:1, 1.5 L each), and 11 fractions (ESE-18-8- 1 to ESE-18-8-11).

1.5×55 cm)을 이용하여 MeOH 710 mL로 용출하였고, 6개의 분획물(ESE-18-8-2-1 ~ ESE-18-8-2-6)을 얻었다. 이후, 상기 6개의 분획물 중 ESE-18-8-2-5 분획물[91.2 mg, Ve/Vt 0.479-0.634]에 대하여 Preparative HPLC (Waters 600S)을 활용하여 정제를 진행하였다. 이때 컬럼으로 Cosmosil 5C18 column (Waters, 5 μm, 250×10 mm)를 사용하였으며, 254 nm 조건하에 isocratic (0.1% formic acid in DW 70%, acetonitrile 30%)조건으로 용출시켰다. 이때 용출속도는 4.0 μL/min로 하였다. 이를 통하여 화합물 14 [60.5 mg, TLC(Kieselgel 60 F₂₅₄) Rf 0.34, CHCl₃-MeOH-물(8:3:1), TLC(RP-18F_254S) Rf 0.56, MeOH-물(2:1)] 및 화합물 1 [30.7 mg, TLC(Kieselgel 60 F₂₅₄) Rf 0.34, CHCl₃-MeOH-물(8:3:1), TLC(RP-18F_254S) Rf 0.56, MeOH-물(2:1)]을 분리하였다.Subsequently, among the 11 fractions, the ESE-18-8-2 fraction [172.4 mg, Ve / Vt 0.090-0.153] was Sephadex LH-20 cc (

1.5 × 55 cm) and eluted with 710 mL of MeOH, and 6 fractions (ESE-18-8-2-1 to ESE-18-8-2-6) were obtained. Thereafter, the ESE-18-8-2-5 fraction [91.2 mg, Ve/Vt 0.479-0.634] among the six fractions was purified using Preparative HPLC (Waters 600S). At this time, Cosmosil 5C18 column (Waters, 5 μm, 250 × 10 mm) was used as a column, and elution was performed under isocratic (0.1% formic acid in DW 70%, acetonitrile 30%) conditions under 254 nm conditions. At this time, the dissolution rate was 4.0 μL/min. Through this, compound 14 [60.5 mg, TLC (Kieselgel 60 F ₂₅₄ ) Rf 0.34, CHCl ₃ -MeOH-water (8: 3: 1), TLC (RP-18F _254S ) Rf 0.56, MeOH-water (2: 1) ] and compound 1 [30.7 mg, TLC (Kieselgel 60 F ₂₅₄ ) Rf 0.34, CHCl ₃ -MeOH-water (8:3:1), TLC (RP-18F _254S ) Rf 0.56, MeOH-water (2:1) ] was isolated.

2.5×6 cm)을 이용하여 MeOH-물 (2:3, 1.5 L)로 용출하였고, 10개의 분획물(ESE-18-8-5-1 ~ ESE-18-8-5-10)을 얻었다. 이후, 상기 10개의 분획물 중 ESE-18-8-5-2 분획물에서 화합물 3 [23.2 mg, Ve/Vt 0.080-0.130, TLC(Kieselgel 60 F₂₅₄) Rf 0.43, EtOAc-BuOH-물(23:3:1), TLC(RP-18F_254S) Rf 0.79, MeOH-물(3:2)]을 분리하였다. 또한 상기 10개의 분획물 중 ESE-18-8-5-5 분획물[100.9 mg, Ve/Vt 0.700-0.860]에 대하여 Preparative HPLC (Waters 600S)을 활용하여 정제를 진행하였다. 이때 컬럼으로 Cosmosil 5C18 column (Waters, 5 μm, 250×10 mm)를 사용하였으며, 254 nm 조건하에 isocratic (0.1% formic acid in DW 70%, acetonitrile 30%)조건으로 용출시켰다. 이때 용출속도는 4.0 μL/min로 하였다. 이를 통하여 화합물 10 [72.8 mg, TLC(Kieselgel 60 F₂₅₄) Rf 0.44, EtOAc-BuOH-물(23:3:1), TLC(RP-18F_254S) Rf 0.51, MeOH-물(3:2)] 및 화합물 11 [28.1 mg, TLC(Kieselgel 60 F₂₅₄) Rf 0.44, EtOAc-BuOH-물(23:3:1), TLC(RP-18F_254S) Rf 0.51, MeOH-물(3:2)]을 분리하였다. 이 과정은 도 2에 나타내었다. 또한, 본 실시예에서 분리한 14종의 페놀화합물의 구조는 도 3에 나타내었다.Subsequently, among the 11 fractions, the ESE-18-8-5 fraction [297.3 mg, Ve / Vt 0.270-0.300] was ODS cc (

2.5 × 6 cm) and eluted with MeOH-water (2:3, 1.5 L), and 10 fractions (ESE-18-8-5-1 to ESE-18-8-5-10) were obtained. Then, compound 3 [23.2 mg, Ve / Vt 0.080-0.130, TLC (Kieselgel 60 F ₂₅₄ ) Rf 0.43, EtOAc-BuOH-water (23:3) in the ESE-18-8-5-2 fraction among the 10 fractions :1), TLC (RP-18F _254S ) Rf 0.79, MeOH-water (3:2)] were separated. Also, the ESE-18-8-5-5 fraction [100.9 mg, Ve/Vt 0.700-0.860] among the 10 fractions was purified using Preparative HPLC (Waters 600S). At this time, Cosmosil 5C18 column (Waters, 5 μm, 250 × 10 mm) was used as a column, and elution was performed under isocratic (0.1% formic acid in DW 70%, acetonitrile 30%) conditions under 254 nm conditions. At this time, the dissolution rate was 4.0 μL/min. Through this, compound 10 [72.8 mg, TLC (Kieselgel 60 F ₂₅₄ ) Rf 0.44, EtOAc-BuOH-water (23: 3: 1), TLC (RP-18F _254S ) Rf 0.51, MeOH-water (3: 2)] and compound 11 [28.1 mg, TLC (Kieselgel 60 F ₂₅₄ ) Rf 0.44, EtOAc-BuOH-water (23:3:1), TLC (RP-18F _254S ) Rf 0.51, MeOH-water (3:2)] separated. This process is shown in Figure 2. In addition, the structures of the 14 phenolic compounds isolated in this Example are shown in FIG.

Example 4. Evaluation of Influenza Virus Inhibitory Activity through Molecular Docking Simulation of Phenolic Compounds Derived from Parmesan Water Extract

For the 14 phenolic compounds isolated in Example 3, molecular docking simulation was performed on the influenza virus to evaluate the virus inhibitory ability.

Specifically, molecular modeling was performed for influenza A/H1N1. The phenolic compound continuously binds to the subunit viral RdRp (PA, PB1, PB2) that affects replication and transcription in the virus. Therefore, in this study, blind docking was performed for the subunit viral RdRp (PA, PB1, PB2). In particular, in the case of PB2, molecular docking simulation was performed for the C-terminal domain, Middle domain and Cap binding domain. Influenza virus also has a Receptor binding domain (RBD) like the spike protein of coronavirus (SARS-CoV-2). RBD; and A pocket, which plays a major role in the process of fusion of cell membranes after RBD enters the cell and before exporting its RNA into the cell. PDB files were obtained and molecular docking simulation was performed. The docking result was obtained in the form of binding affinity in Kcal/mol unit, and the docking process was repeated 10 times on 10 separate computer systems. The binding mode was visualized using Discovery Studio 4.0, and 2D or 3D images were used to confirm molecular interactions. The results are shown in Figures 4a to 4e. Also, the average binding energy values calculated after docking of compounds 1 to 14 are shown in Table 1.

As shown in FIGS. 4a to 4e and Table 1, it was confirmed that all the phenolic compounds derived from the freshwater extract showed high in silico binding ability through the three-dimensional structure-based docking of influenza virus, and among them, compound 2 had the highest It was confirmed that the inhibitory ability was shown.

Compounds Average Binding Affinity (Kcal/mol) PA PB1 PB2 RBD A pocket C-terminal domain Middle domain Cap binding domain Compound 1 (Formula 3) -8.22 -3.47 -8.02 -4.94 -6.84 -6.91 -6.04 Compound 2 (Formula 4) -14.17 -8.05 -14.53 -11.14 -10.6 -12.27 -14.67 Compound 3 (Formula 5) -8.93 -1.68 -5.55 -0.47 -3.86 -5.26 -5.57 Compound 4 (Formula 6) -5.83 -4.39 -6.59 -5.26 -7.03 -6.98 -9.53 Compound 5 (Formula 7) -7.88 -5.23 -6.91 -5.08 -7.21 -8.38 -9.13 Compound 6 (Formula 8) -6.55 -3.20 -6.88 -3.83 -5.81 -6.98 -5.87 Compound 7 (Formula 9) -6.78 -4.46 -5.82 -4.57 -5.45 -7.38 -6.36 Compound 8 (Formula 10) -6.88 -3.83 -7.59 -4.80 -7.00 -7.10 -8.49 Compound 9 (Formula 11) -6.54 -4.30 -7.48 -4.64 -7.33 -7.02 -7.68 Compound 10 (Formula 12) -6.61 -2.85 -6.64 -3.9 -6.35 -6.35 -6.19 Compound 11 (Formula 13) -6.34 -2.85 -6.35 -3.63 -5.87 -6.61 -5.49 Compound 12 (Formula 14) -6.08 -3.10 -5.14 -3.56 -4.76 -6.97 -5.83 Compound 13 (Formula 15) -6.78 -3.68 -6.67 -4.22 -6.61 -6.63 -8.36 Compound 14 (Formula 16) -6.74 -1.93 -6.96 -3.63 -5.64 -5.93 -5.55

Example 5. Cell culture

The MDCK cell line used in the experiment was maintained at 37°C and 5% CO ₂ in MEM (Minimum essential medium, Gibco) medium.

Example 6. Confirmation of cytotoxicity of fresh water extract

MDCK cells were seeded in a 96 well-plate at a concentration of 1×10 ⁵ cells/well. Cytopathic effect (CPE) and cell viability of freshwater extract after culturing for 24 hours in a CO ₂ incubator at 37℃ and treating with freshwater extract at different concentrations (2.5, 5, 10 μg/mL) for 24 hours was measured. The results are shown in FIG. 5 .

As shown in FIG. 5 , it was confirmed that the freshwater extract had no morphological changes and no cytotoxicity.

Example 7. Investigation of antiviral activity of dampalsu extract-1

MDCK cells cultured in MEM medium were seeded in a 24 well-plate at a concentration of 1×10 ⁵ cells/well. After culturing for 24 hours in a CO ₂ incubator at 37°C, removing the cell medium, and treating influenza A virus (IAV/California/2007/H1N1) for 1 hour at an MOI of 0.1, freshwater extracts were prepared at different concentrations (2.5, 5, 10 μg/mL) for 24 hours. After 24 hours, the cells were washed three times with PBS, and then fixed with 4% formaldehyde for 10 minutes. Thereafter, the cells were stained with 1% crystal violet to measure the cytopathic effect (CPE) of the cells. The results are shown in FIG. 6 .

As shown in FIG. 6 , when the freshwater extract was treated, it was confirmed that IAV-induced CPE was decreased in a concentration-dependent manner, and cell viability was also increased.

Example 8. Investigation of antiviral activity of the extract of dampalsu-2

MDCK cells cultured in MEM medium were seeded in a 6 well-plate at a concentration of 2×10 ⁵ cells/well. Incubated for 24 hours in a CO ₂ incubator at 37°C, the cell medium was removed, and influenza A virus (IAV/California/2007/H1N1) was treated at 0.1 MOI for 1 hour. 10 μg/mL) for 24 hours. After 24 hours, RNA was extracted from the cells using RANiso Plus (Takara). The isolated RNA was quantified using a nanodrop, synthesized into cDNA using a cDNA synthesis kit (RevertraAce qPCR RT kit, Toyobo), and real-time PCR was performed using a CFX Connect real-time system (Bio-rad). Primer reaction conditions were prewarmed at 95 ° C for 10 minutes, and a total of 40 cycles were repeated at 95 ° C for 15 seconds and 60 ° C for 1 minute. Then, the expression of M1 and nucleoprotein (NP) genes, which form the structure of influenza virus, was confirmed. The results are shown in Figure 7a. In addition, the sense and antisense sequences of the primers are shown in Table 2.

In addition, MDCK cells were treated with 0.1 MOI of IAV for 1 hour, followed by treatment with freshwater extract for 24 hours. Then, after fixing the cells, they were stained with DAPI and mouse monoclonal anti-viral NP, and the IAV inhibitory effect of the freshwater extract was measured by confocal microscopy. The results are shown in Figure 7b.

As shown in FIGS. 7A and 7B , both M1 and NP gene expressions were suppressed when the freshwater extract was treated, and as a result of staining with anti-viral NP, the expression level of viral NP was suppressed in the freshwater extract. This means that the dampalsu extract exhibits very good antiviral efficacy.

M1 primer Sense 5'-AAGACCAATCCTGTCACCTCTG-3' Antisense 5'-CAAAACGTCTACGCTGCAGTCC-3' NP primers Sense 5'-CCAGATCAGTGTGCAGCCTA-3' Antisense 5'-CTTCTGGCTTTGCACTTTCC-3' GAPDH primers Sense 5'-TGGACCTGACCTGCCGTCTA-3' Antisense 5'-CCCTGTTGCTGTAGCCAAATTC-3'

Example 9. Investigation of antiviral activity of freshwater extract-3

MDCK cells cultured in MEM medium were seeded in a 6 well-plate at a concentration of 2×10 ⁵ cells/well. After culturing for 24 hours in a CO ₂ incubator at 37°C, removing the cell medium, and treating influenza A virus (INV/California/2007/H1N1) at an MOI of 0.1 for 1 hour, freshwater extracts were prepared at different concentrations (0.4, 2, 10 μg/mL) for 24 hours. After 24 hours, proteins were extracted with a protein extraction solution (Elpisbio), electrophoresed on an SDS-polyacrylamide gel, and transferred to a nicrocellulose membrane. The transcribed membrane was blocked with 5% skim milk at room temperature for 1 hour, reacted with the primary antibody at 4°C for 16 hours, and then washed with TBST buffer 5 times or more. The membrane was reacted with the secondary antibody for 1 hour at room temperature, and then washed five or more times with TBST buffer. The ECL solution was reacted and the protein expression level was measured using a Chemidoc™ image analyzer and then quantified. The results are shown in Figure 7c.

As shown in Figure 7c, it was confirmed that the expression of M1, which forms the influenza virus structure, was reduced when the freshwater extract was treated. This means that the extract of dampalsu has an inhibitory effect on influenza virus.

Example 10. Confirmation of cytotoxicity of Compounds 2 and 3 derived from fresh water extract

MDCK cells were seeded in a 96 well-plate at a concentration of 1×10 ⁵ cells/well. After culturing for 24 hours in a CO ₂ incubator at 37℃ and treating for 24 hours with compounds 2 and 3, freshwater extract components, by concentration (2.5, 5, 10 μg/mL), cytopathic effect (CPE) and cell viability was measured.

As shown in FIG. 8 , it was confirmed that there was no morphological change or cytotoxicity of the cells due to the treatment with Compounds 2 and 3, which are components of the freshwater extract.

Example 11. Investigation of antiviral activity of Compounds 2 and 3 derived from fresh water extract-1

MDCK cells cultured in MEM medium were seeded in a 24 well-plate at a concentration of 1×10 ⁵ cells/well. After culturing for 24 hours in a 37°C, CO ₂ incubator, removing the cell medium, and treating influenza A virus (IAV/California/2007/H1N1) at 0.1 MOI for 1 hour, compounds 2 and 3 were added at each concentration (2.5 , 5, 10 μg/mL) for 24 hours. After 24 hours, the cells were washed three times with PBS, and then fixed with 4% formaldehyde for 10 minutes. Thereafter, the cells were stained with 1% crystal violet to measure the cytopathic effect (CPE) of the cells. The results are shown in FIG. 9 .

As shown in FIG. 9, when the compounds 2 and 3 were treated, it was confirmed that the CPE by IAV was decreased in a concentration-dependent manner, and the cell viability was also increased.

Example 12. Investigation of antiviral activity of compounds 2 and 3 derived from fresh water extract-2

MDCK cells cultured in MEM medium were seeded in a 6 well-plate at a concentration of 2×10 ⁵ cells/well. After culturing for 24 hours in a 37°C, CO ₂ incubator, removing the cell medium, and treating influenza A virus (IAV/California/2007/H1N1) for 1 hour at an MOI of 0.1, compounds 2 and 3 were added at each concentration (2.5 , 5, 10 μg/mL) for 24 hours. After 24 hours, RNA was extracted from the cells using RANiso Plus (Takara). The isolated RNA was quantified through Nanodrop, synthesized into cDNA using a cDNA synthesis kit (RevertraAce qPCR RT kit, Toyobo), and real-time PCR was performed using a CFX Connect real-time system (Bio-rad). Primer reaction conditions were prewarmed at 95 ° C for 10 minutes, and a total of 40 cycles were repeated at 95 ° C for 15 seconds and 60 ° C for 1 minute. Then, expression of M1 and nucleoprotein (NP) genes, which form the structure of influenza virus, and IAV viral titer were confirmed. The results are shown in Figure 10a.

In addition, MDCK cells were treated with 0.1 MOI of IAV for 1 hour, followed by treatment with freshwater extract for 24 hours. Then, after fixing the cells, staining with DAPI and mouse monoclonal anti-viral NP (mouse monoclonal anti-viral NP), IAV inhibitory efficacy of compounds 2 and 3 derived from freshwater extract was measured by confocal microscopy did The results are shown in Figure 10b.

As shown in FIGS. 10A and 10B , when compounds 2 and 3 were treated, both M1 and NP gene expressions were suppressed, and the IAV viral titer was decreased. In addition, the expression level of viral NP was suppressed in the result of staining with anti-viral NP. This means that the compounds 2 and 3 derived from the extract of damsel water show very good antiviral efficacy.

Example 13. Investigation of antiviral activity of compounds 2 and 3 derived from fresh water extract-3

MDCK cells cultured in MEM medium were seeded in a 6 well-plate at a concentration of 2×10 ⁵ cells/well. After culturing for 24 hours in a 37°C, CO ₂ incubator, removing the cell medium, and treating influenza A virus (INV/California/2007/H1N1) for 1 hour at an MOI of 0.1, compound 2 (2.5, 5, 10 μg/ mL) and compound 3 (0.4, 2, 10 μg/mL) at each concentration for 24 hours. After 24 hours, proteins were extracted with a protein extraction solution, electrophoresed on an SDS-polyacrylamide gel, and transferred to a nicrocellulose membrane. The transcribed membrane was blocked with 5% skim milk at room temperature for 1 hour, reacted with the primary antibody at 4°C for 16 hours, and then washed with TBS-T buffer 5 times or more. The membrane was reacted with the secondary antibody for 1 hour at room temperature, and then washed five or more times with TBS-T buffer. The ECL solution was reacted and the protein expression level was measured using a Chemidoc™ image analyzer and then quantified. The results are shown in Figure 10c.

As shown in FIG. 10c , when compounds 2 and 3 were treated, it was confirmed that the expression levels of M1, which forms the influenza virus structure, and NS1, which determines the pathogenicity of the influenza virus, were reduced. This means that the compounds 2 and 3 derived from the freshwater extract have an inhibitory effect on influenza virus.

Example 14. Animal testing

14-1. laboratory animal

Six-week-old C57BL/6 male mice were used, and the safety of the administered virus was secured, but contact with other animals was blocked using a negative rearing system due to concerns about infection of other rodents. Isolation, identification, titer calculation, and administration of the virus were performed on a special clean bench prepared to ensure its safety, and disinfection was performed before and after the experiment using a special disinfectant for virus disinfection. For the management of feed feeding, which can directly affect body weight, the amount of feed was judged and fed every day so that there was no restriction in feeding. Lighting was changed every 12 hours, and water and food were freely available. Other matters related to animal breeding were performed in accordance with Chung-Ang University Animal Experiment Ethics Committee (National Association of Laboratory Animal Care) regulations.

14-2. intranasal administration

To evaluate the anti-influenza efficacy, 6-week-old C57BL/6 male mice were intranasally infected with 1×10 ³ PFU of IAV, and 10 minutes, 3 hours, and 6 hours after infection, the mice were injected with freshwater extract and compounds 2 and 3. After intranasal administration, mouse body weight and mortality were observed for 14 days. The results are shown in Figures 11a and 11b.

As shown in FIG. 11A, the control group showed a survival rate of 20% on the 10th day of IAV infection, whereas the group administered with freshwater extract showed a survival rate of 80%, and the group administered with Compounds 2 and 3 showed a survival rate of 100%. greatly increased.

In addition, as shown in FIG. 11B, with regard to the change in body weight during the experiment, the control group showed a decrease in body weight after infection, whereas when the freshwater extract and compounds 2 and 3 were intranasally administered, the width of the body weight loss decreased compared to the control group. weight was recovered after the 8th day of infection. Therefore, it was confirmed that when intranasal administration of the freshwater extract and compounds 2 and 3 was effective in alleviating the symptoms of influenza virus infection.

14-3. oral administration

To evaluate the anti-influenza efficacy, mice were anesthetized and infected with IAV at 1×10 ³ pfu through the nasal cavity. Then, the extract of dampalsu (0.5 mg/kg) was orally administered from 3 days before IAV infection to 5 days after infection for a total of 8 days, and on the 5th day after infection, the mice were sacrificed and viral RNA was extracted from the lungs. The body weight of the mouse was observed for 8 days, and the expression level of M1, which forms an influenza virus structure in the mouse lung, was confirmed. The results are shown in Figures 12a and 12b.

As shown in FIG. 12a , in the control group, a decrease in body weight was observed after IAV infection, but in the oral administration group of dampalsu extract, it was confirmed that the weight loss was suppressed compared to the control group.

In addition, as shown in FIG. 12B, it was confirmed that the expression of M1 was suppressed in the freshwater extract treatment group compared to the control group.

As described above, the specific embodiments of the present invention have been described in detail, but those skilled in the art who understand the spirit of the present invention may add, change, delete, etc. other components within the scope of the same idea, and other degenerate inventions. However, other embodiments included within the scope of the present invention can be easily suggested. Therefore, the embodiments described above should be understood as illustrative in all respects and not limiting. The scope of the present invention is indicated by the claims to be described later rather than the above detailed description, and all changes or modifications derived from the meaning and scope of the claims and equivalent concepts thereof are included in the scope of the present invention. should be interpreted as

Claims (17)

A pharmaceutical composition for the prevention or treatment of influenza virus infection, comprising an extract or a fraction thereof as an active ingredient.
According to claim 1,
The freshwater extract is extracted with one or more solvents selected from the group consisting of water, C ₁ to C ₄ alcohol, ethyl acetate, chloroform and hexane, and mixed solvents thereof. Pharmaceutical for preventing or treating influenza virus infection enemy composition.
According to claim 1,
The fraction is extracted with one or more solvents selected from the group consisting of water, alcohols having 1 to 4 carbon atoms, polar solvents, ethyl acetate, normal butanol ( n -Butanol), non-polar solvents, and mixed solvents thereof Characterized in, a pharmaceutical composition for preventing or treating influenza virus infection.
According to claim 1,
The pharmaceutical composition for preventing or treating influenza virus infection, characterized in that the extract of dampalsu is extracted using 30 to 70% ethanol.
According to claim 1,
The influenza virus is a pharmaceutical composition for preventing or treating influenza virus infection, characterized in that the influenza A type H1N1 virus.
According to claim 1,
The pharmaceutical composition for preventing or treating influenza virus infection, characterized in that the extract of Dampalsu inhibits the expression of at least one selected from the group consisting of M1 and NP genes of influenza virus.
A pharmaceutical composition for preventing or treating influenza virus infection, comprising at least one selected from the group consisting of a compound represented by the following formula (1) and pharmaceutically acceptable salts thereof:
[Formula 1]

In Formula 1,
When R ₂ is hydrogen,
R ₁ is hydrogen, a hydroxy group, C ₁ -C ₁₆ alkyl, C ₁ -C ₁₅ alkoxy, C ₃ -C ₁₆ cyclic alkyl, C ₂ -C ₁₅ heterocyclic alkyl,

,

,

,

,

,

or

ego;

When R ₂ is a hydroxyl group,
R ₁ is a hydroxy group, C ₁ -C ₁₀ alkyl, C ₁ -C ₉ alkoxy, C ₃ -C ₁₀ cyclic alkyl, C ₂ -C ₁₀ heterocyclic alkyl,

,

,

or

am.
A pharmaceutical composition for preventing or treating influenza virus infection, comprising at least one selected from the group consisting of a compound represented by the following formula (2) and pharmaceutically acceptable salts thereof:
[Formula 2]

n is an integer from 0 to 3;
R ₃ is hydrogen, hydroxy group, C ₁ -C ₁₀ alkyl, C ₁ -C ₉ alkoxy, C ₃ -C ₁₀ cyclic alkyl, C ₂ -C ₉ heterocyclic alkyl, or

ego;

R ₄ is hydrogen, a hydroxyl group, C ₁ -C ₁₀ alkyl, C ₁ -C ₉ alkoxy, C ₃ -C ₁₀ cyclic alkyl, C ₂ -C ₉ heterocyclic alkyl, or

ego;
Optionally, adjacent substituents among R ₃ to R ₄ may be linked to form a ring;
R _3a is an oxygen or hydroxyl group;
R _3b and R _4a may be connected to form a ring;
The R _3c and R _4b may be connected to form a ring.
According to claim 7 or 8,
The compound is a composition for preventing or treating influenza virus infection, characterized in that at least one selected from the group consisting of compounds represented by the following formulas 3 to 16.
[Formula 3]

[Formula 4]

[Formula 5]

[Formula 6]

[Formula 7]

[Formula 8]

[Formula 9]

[Formula 10]

[Formula 11]

[Formula 12]

[Formula 13]

[Formula 14]

[Formula 15]

[Formula 16]

A food composition for preventing or ameliorating influenza virus infection, comprising an extract of fresh water as an active ingredient.
A food composition for preventing or improving influenza virus infection, characterized in that it contains at least one selected from the group consisting of a compound represented by the following formula (1) and a food-acceptable salt thereof:
[Formula 1]

In Formula 1,
When R ₂ is hydrogen,
R ₁ is hydrogen, a hydroxy group, C ₁ -C ₁₆ alkyl, C ₁ -C ₁₅ alkoxy, C ₃ -C ₁₆ cyclic alkyl, C ₂ -C ₁₅ heterocyclic alkyl,

,

,

,

,

,

or

ego;

When R ₂ is a hydroxyl group,
R ₁ is a hydroxy group, C ₁ -C ₁₀ alkyl, C ₁ -C ₉ alkoxy, C ₃ -C ₁₀ cyclic alkyl, C ₂ -C ₁₀ heterocyclic alkyl,

,

,

or

am.
A food composition for preventing or improving influenza virus infection, characterized in that it contains at least one selected from the group consisting of a compound represented by the following formula (2) and a food-acceptable salt thereof:
[Formula 2]

n is an integer from 0 to 3;
R ₃ is hydrogen, hydroxy group, C ₁ -C ₁₀ alkyl, C ₁ -C ₉ alkoxy, C ₃ -C ₁₀ cyclic alkyl, C ₂ -C ₉ heterocyclic alkyl, or

ego;

R ₄ is hydrogen, a hydroxyl group, C ₁ -C ₁₀ alkyl, C ₁ -C ₉ alkoxy, C ₃ -C ₁₀ cyclic alkyl, C ₂ -C ₉ heterocyclic alkyl, or

ego;
Optionally, adjacent substituents among R ₃ to R ₄ may be linked to form a ring;
R _3a is an oxygen or hydroxyl group;
R _3b and R _4a may be connected to form a ring;
The R _3c and R _4b may be connected to form a ring.
According to any one of claims 10 to 12,
The food composition is a food composition for preventing or improving influenza virus infection, characterized in that the health functional food composition.
A quasi-drug composition for preventing or inhibiting influenza virus infection, comprising an extract of dampalsu as an active ingredient.
According to claim 14,
The quasi-drug is a quasi-drug composition for preventing or suppressing influenza virus infection, characterized in that at least one selected from the group consisting of disinfectant cleaner, shower foam, gargreen, wet tissue, detergent soap, hand wash and ointment.
A quasi-drug composition for preventing or inhibiting influenza virus infection, characterized in that it contains at least one selected from the group consisting of a compound represented by Formula 1 and pharmaceutically acceptable salts thereof:
[Formula 1]

In Formula 1,
When R ₂ is hydrogen,
R ₁ is hydrogen, a hydroxy group, C ₁ -C ₁₆ alkyl, C ₁ -C ₁₅ alkoxy, C ₃ -C ₁₆ cyclic alkyl, C ₂ -C ₁₅ heterocyclic alkyl,

,

,

,

,

,

or

ego;

When R ₂ is a hydroxyl group,
R ₁ is a hydroxy group, C ₁ -C ₁₀ alkyl, C ₁ -C ₉ alkoxy, C ₃ -C ₁₀ cyclic alkyl, C ₂ -C ₁₀ heterocyclic alkyl,

,

,

or

am.
A quasi-drug composition for preventing or inhibiting influenza virus infection, characterized in that it contains at least one selected from the group consisting of a compound represented by the following formula (2) and pharmaceutically acceptable salts thereof:
[Formula 2]

n is an integer from 0 to 3;
R ₃ is hydrogen, hydroxy group, C ₁ -C ₁₀ alkyl, C ₁ -C ₉ alkoxy, C ₃ -C ₁₀ cyclic alkyl, C ₂ -C ₉ heterocyclic alkyl, or

ego;

R ₄ is hydrogen, a hydroxyl group, C ₁ -C ₁₀ alkyl, C ₁ -C ₉ alkoxy, C ₃ -C ₁₀ cyclic alkyl, C ₂ -C ₉ heterocyclic alkyl, or

ego;
Optionally, adjacent substituents among R ₃ to R ₄ may be linked to form a ring;
R _3a is an oxygen or hydroxyl group;
R _3b and R _4a may be connected to form a ring;
The R _3c and R _4b may be connected to form a ring.

Images